LILRA2 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8N149 |
---|---|
Other Accession | NP_006857.1, NP_001124389.1 |
Clone Names | 90713127 |
Gene ID | 11027 |
---|---|
Other Names | Leukocyte immunoglobulin-like receptor subfamily A member 2, CD85 antigen-like family member H, Immunoglobulin-like transcript 1, ILT-1, Leukocyte immunoglobulin-like receptor 7, LIR-7, CD85h, LILRA2, ILT1, LIR7 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | LILRA2 |
---|---|
Synonyms | ILT1, LIR7 |
Function | Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061). |
Cellular Location | Cell membrane; Single-pass type I membrane protein |
Tissue Location | Detected on the surface of all peripheral blood monocytes, neutrophils, basophils and eosinophils (at protein level) (PubMed:12529506, PubMed:22479404). Expression levels are very low or not detectable on monocytes, T-cells, B-cells, dendritic cells and natural killer (NK) cells (PubMed:9548455) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Leukocyte Ig-like receptors (LIRs) are a family ofimmunoreceptors expressed predominantly on monocytes and B cellsand at lower levels on dendritic cells and natural killer (NK)cells. All LIRs in subfamily B have an inhibitory function (see,e.g., LILRB1, MIM 604811). LIRs in subfamily A, with shortcytoplasmic domains lacking an immunoreceptor tyrosine-basedinhibitory motif (ITIM) and with transmembrane regions containing acharged arginine residue, may initiate stimulatory cascades. Onemember of subfamily A (LILRA3; MIM 604818) lacks a transmembraneregion and is presumed to be a soluble receptor.
References
Mosbruger, T.L., et al. J. Infect. Dis. 201(9):1371-1380(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Jones, D.C., et al. Eur. J. Immunol. 39(11):3195-3206(2009)Chen, Y., et al. J. Mol. Biol. 386(3):841-853(2009)Mamegano, K., et al. Genes Immun. 9(3):214-223(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.